Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukaemia -- a developmental perspective.

Shai Izraeli1

  • 1Department of Paediatric Haemato-Oncology, Sackler Faculty of Medicine, Cancer Research Centre, Safra's Children's Hospital, Sheba Medical Centre, Tel-Aviv University, Tel-Hashomer, Ramat-Gan, Israel. izraelis@netvision.net.il

British Journal of Haematology
|June 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cracking the nut of NUTM1 rearrangements in infant leukemia.

Blood·2026
Same author

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Brain tumor classification from FFPE samples using nanopore methylation sequencing.

NAR cancer·2025
Same author

Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy.

HemaSphere·2025
Same author

Pediatric acute leukemias and myelodysplastic syndromes, progress and challenges: introduction to a review series.

Haematologica·2025

Leukaemia develops from abnormal blood cell precursors due to gene mutations. This review examines how genetic changes in RUNX1, GATA1, SCL, and LMO2 drive leukaemogenesis, particularly in specific leukaemias.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Leukaemia is defined by the accumulation of malignant hematopoietic precursors.
  • Acquired genetic alterations impacting normal hematopoiesis are common in leukaemia.
  • Leukaemic progression relies on secondary mutations that enhance the survival of arrested cells.

Purpose of the Study:

  • To review the general paradigm of leukaemogenesis.
  • To present three specific examples illustrating this paradigm.
  • To highlight the roles of key genes in leukaemic development.

Main Methods:

  • Literature review of recent studies on leukaemogenesis.
  • Analysis of genetic alterations in specific leukaemic subtypes.
  • Description of gene functions and their dysregulation in cancer.

Related Experiment Videos

Main Results:

  • RUNX1 gene abnormalities are implicated in acute leukaemias.
  • GATA1 mutations are associated with leukaemias in Down syndrome.
  • Ectopic expression of SCL and LMO2 genes contributes to T cell acute lymphoblastic leukaemia.

Conclusions:

  • Genetic alterations are fundamental to leukaemogenesis.
  • Specific gene mutations provide distinct pathways to leukaemia development.
  • Understanding these genetic mechanisms is crucial for targeted therapies.